Gap in non-oral prescriptions relative to AHS guidelines represents an opportunity to increase awareness of Tonix’s two FDA-approved non-oral treatments for acute migraineZembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) are indicated for the treatment of acute migraine in adultsCHATHAM, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp.

非口服处方相对于AHS指南的差距代表了一个机会，可以提高人们对Tonix的两种FDA批准的急性偏头痛非口服治疗的认识Zembrace®SymTouch®（舒马普坦注射液）和Tosymra®（舒马普坦鼻喷雾剂）用于治疗成人急性偏头痛Schatham，N.J.，2024年6月18日（环球新闻网）——Tonix Pharmaceuticals Holding Corp。

(Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data from a poster presentation at the 66th Annual Scientific Meeting of the American Headache Society (AHS), held June 13-16, 2024. A copy of the Company’s poster presentation is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.In the poster presentation titled, “American Headache Society Consensus Statement and Other Recommendations: How Many Practitioners Comply With the Recommendations?,” a retrospective review of real-world data compares real world usage of non-oral migraine products with the most recent AHS consensus statement.

（纳斯达克：TNXP）（Tonix或该公司）是一家完全整合的生物制药公司，拥有上市产品和一系列开发候选人，在2024年6月13日至16日举行的美国头痛学会（AHS）第66届年度科学会议上发布了海报上的数据。该公司海报的副本可在Tonix网站www.tonixpharma.com的“科学演示”选项卡上找到。在题为“美国头痛协会共识声明和其他建议：有多少从业者遵守建议？”的海报演示中，“对现实世界数据的回顾性审查将非口服偏头痛产品的现实世界使用与最新的AHS共识声明进行了比较。

The data reaffirms several past recommendations from the AHS and stresses the need for customizing treatment of migraine headaches to the needs of patients, as well as using the most appropriate route of administration for any given acute attack based on the clinical presentation. So far, real world data show that compliance with the guidelines and the consensus statement have yet to be achieved but has the potential to be increased.

这些数据重申了AHS过去的几项建议，并强调需要根据患者的需要定制偏头痛的治疗方法，以及根据临床表现对任何给定的急性发作使用最合适的给药途径。到目前为止，真实世界的数据表明，尚未实现对准则和共识声明的遵守，但仍有可能增加。

Specifically, the data show the use of non-oral drugs for treating an acute migraine attack was only 7% in 2012 and has decreased to below 4% in 2023, when the potential need for such drugs is anticipated to be a signif.

具体而言，数据显示，2012年用于治疗急性偏头痛发作的非口服药物的使用率仅为7%，2023年降至4%以下，预计对此类药物的潜在需求将是显着的。